Intensity Therapeutics Resumes TNBC Trial with Adjusted Dosing
Event summary
- Intensity Therapeutics resumed patient treatment in the INVINCIBLE-4 Phase 2 trial for triple-negative breast cancer (TNBC) on July 15, 2026.
- The trial evaluates INT230-6 combined with standard-of-care neoadjuvant immuno-chemotherapy versus SOC alone.
- Protocol amendments include a lower drug-to-tumor volume ratio and single injection of INT230-6 to address skin irritation issues.
- Prior to the pause, 14 patients were treated, with favorable safety trends observed in the INT230-6 cohort.
The big picture
Intensity Therapeutics' resumption of the INVINCIBLE-4 trial addresses a critical unmet need in TNBC treatment, where current standard-of-care regimens yield only 63% pCR rates and high toxicity. The company's intratumoral approach with INT230-6 aims to improve outcomes by leveraging localized drug delivery and immune activation. Success in this trial could position Intensity as a key player in the evolving landscape of precision oncology, particularly for aggressive cancer subtypes.
What we're watching
- Clinical Efficacy
- Whether INT230-6 can demonstrate superior pCR rates compared to SOC alone in the expanded patient cohort.
- Safety Profile
- The impact of dosing adjustments on reducing skin irritation and other adverse events.
- Regulatory Pathway
- The pace at which Intensity Therapeutics can advance INT230-6 through Phase 2/3 trials for TNBC.
Related topics